Are HGTs hazardous drugs? This month, IBC Director Patrick Conley offered a comprehensive overview of the topic.

IBC Director Patrick Conley:

"The increasing number of human trials evaluating the use of biologics to treat human disease has introduced a number of new and unique exposure risks in healthcare. As safety professionals begin to assess these novel hazards and the associated exposures risks, they will need to establish a greater understanding of the healthcare workplace, workforce, and work practices, as well as the standards and regulations that govern and direct healthcare operations. Pivotal to the connection of biologics and healthcare operations is a focused determination on whether these medications are considered hazardous by the institution in accordance with USP800.

Curious about the potential risks involved with your HGT studies? Contact us today with your questions.

Mission Statement

SABAI Global's Mission is to be considered a "World Renowned Thought Leader" in the IBC and IRB space, facilitating positive change in medicine and in the lives of many people; and maintaining the status of an "Employer of Choice" by demonstrating daily, the value we place on our employees, consultants and partners.